|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.80 / 5.68|
More Immunotherapy Buyouts Likely After Kite Sale
Patent Broadly Protects the Use of Prostaglandins for Enhancing Gene Transfer in Blood Stem Cells
Fate's first subject has been treated with FATE-NK100 for AML and two additional clinical trials of FATE-NK100 for the treatment of multiple advanced solid tumor types will soon open.
New Preclinical Data to be Presented on First-of-Kind Product Candidates Derived from Master Engineered Pluripotent Cell Lines
Some small names are interesting, but more-aggressive position trades are not developing right now.
Insiders have an edge in this complex sector, so it's worth checking them out.
I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.
Traders are also looking for smaller-caps that can move big around the holiday.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.